⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458900 | 0.73 | — | — | |
| SCHEMBL457345 | 0.73 | — | — | |
| SCHEMBL11533604 | 0.69 | — | — | |
| SCHEMBL8170679 | 0.69 | — | — | |
| SCHEMBL4771228 | 0.69 | — | — | |
| SCHEMBL351401 | 0.64 | — | — | |
| SCHEMBL20209043 | 0.63 | — | — | |
| SCHEMBL19608190 | 0.63 | MLYCD (0.36) | — | |
| SCHEMBL642781 | 0.62 | — | — | |
| SCHEMBL27245 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-11-20 | — | — | US | disclosed |
| EP-4634192-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024128741-A9 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-05-30 | — | — | WO | disclosed |
| CN-114466850-B | [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine | 拜耳股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2024128741-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2024-06-20 | — | — | WO | disclosed |
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-07-18 | — | — | US | disclosed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20130018030-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-17 | — | — | US | disclosed |
| WO-2012170702-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012037393-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |